XML 46 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenue from Significant Partners

Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:

			Year ended December 31,
			2023						2022						2021
Partner A			33%						45%						47%
Partner B			20%						16%						12%
Partner C			10%						<10%						<10%

Schedule of Disaggregation of Revenue

Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):

						Year ended December 31,
						2023						2022						2021
Kyprolis						$	35,640					$	30,116					$	27,472
Evomela						10,212						10,197						10,079
Teriparatide injection						11,061						15,785						5,260
Rylaze						13,520						8,796						2,420
Other						13,477						7,633						3,696
						$	83,910					$	72,527					$	48,927

The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):

						Year ended December 31,
						2023						2022						2021
Captisol
Captisol - Core						$	28,372					$	16,429					$	23,423
Captisol - COVID(a)						—						88,066						140,827
						$	28,372					$	104,495					$	164,250
Contract
Service Revenue						$	615					$	1,117					$	3,737
License Fees						217						2,849						634
Milestone						16,800						9,150						17,584
Other						1,400						6,107						6,412
						$	19,032					$	19,223					$	28,367

(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.

Schedule of Computation of Basic and Diluted Net Income (Loss) per Share

The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):

			Year Ended December 31,
			2023						2022						2021
Weighted average shares outstanding:			17,298						16,868						16,630
Dilutive potential common shares:
Restricted stock			85						—						96
Stock options			255						—						520
2023 Convertible Senior Notes			119						—						—
Shares used to compute diluted income per share			17,757						16,868						17,246
Potentially dilutive shares excluded from calculation due to anti-dilutive effect			4,357						6,241						4,793

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration